Seven research firms covering Integra LifeSciences have assigned an average rating of Reduce, with three sell recommendations, two holds and two buys. The mean 12-month price objective across those analysts is fifteen dollars. Notable changes include a restated sell opinion by Weiss Ratings on December 29, an upgrade from hold to buy by Wall Street Zen on November 8, and mixed adjustments of target objectives and underweight or hold ratings from JPMorgan Chase & Co., Truist Financial and Citigroup during the October–November period.

In its third quarter, Integra reported earnings per share of fifty-four cents, surpassing the consensus estimate by eleven cents, while revenue reached four hundred two million dollars, trailing estimates by twelve million. The company achieved a return on equity of 14.06% despite a negative net margin of 30.15%. Revenue grew 5.6% year-over-year. Management has issued guidance for the fourth quarter EPS in a range from 0.790 to 0.840 and full-year EPS between 2.190 and 2.240, compared with analysts’ aggregate forecast of 2.45 for the current fiscal year.

Director Jeffrey A. Graves increased his holding by purchasing 9,000 shares on November 5, lifting his ownership by 28.05% to a total of 41,086 shares. Corporate insiders now control 3.54% of the company’s stock. On the institutional side, MIRAE ASSET GLOBAL ETFS boosted its position by 5.1% to 40,441 shares in the first quarter, Dynamic Technology Lab initiated a new stake of an undisclosed size, Goldman Sachs raised its holdings by 2.2% to 1,660,511 shares, and UBS Asset Management added 23.0% more shares to reach 244,335. Institutional investors collectively own 84.78% of Integra shares.